La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
AlzChem Group Croissance future
Future contrôle des critères 2/6
AlzChem Group is forecast to grow earnings and revenue by 9.6% and 5% per annum respectively. EPS is expected to grow by 9.6% per annum. Return on equity is forecast to be 23.5% in 3 years.
Informations clés
9.6%
Taux de croissance des bénéfices
9.6%
Taux de croissance du BPA
| Chemicals croissance des bénéfices | 39.5% |
| Taux de croissance des recettes | 5.0% |
| Rendement futur des capitaux propres | 23.5% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 19 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04
AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11
Update: AlzChem Group (ETR:ACT) Stock Gained 13% In The Last Year
Aug 07Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?
Jul 20Does This Valuation Of AlzChem Group AG (ETR:ACT) Imply Investors Are Overpaying?
Jul 03Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 629 | 59 | 31 | 87 | 4 |
| 12/31/2025 | 600 | 55 | 20 | 79 | 4 |
| 12/31/2024 | 567 | 50 | 43 | 79 | 4 |
| 6/30/2024 | 557 | 46 | 72 | 97 | N/A |
| 3/31/2024 | 546 | 39 | 73 | 96 | N/A |
| 12/31/2023 | 546 | 35 | 52 | 73 | N/A |
| 9/30/2023 | 528 | 30 | 17 | 55 | N/A |
| 6/30/2023 | 549 | 28 | 15 | 53 | N/A |
| 3/31/2023 | 570 | 30 | -15 | 12 | N/A |
| 12/31/2022 | 550 | 30 | -33 | -4 | N/A |
| 9/30/2022 | 534 | 29 | -25 | 4 | N/A |
| 6/30/2022 | 487 | 28 | -28 | 0 | N/A |
| 3/31/2022 | 454 | 27 | 3 | 29 | N/A |
| 12/31/2021 | 429 | 28 | 14 | 43 | N/A |
| 9/30/2021 | 420 | 27 | 11 | 40 | N/A |
| 6/30/2021 | 406 | 26 | 34 | 63 | N/A |
| 3/31/2021 | 397 | 23 | 14 | 48 | N/A |
| 12/31/2020 | 386 | 20 | 20 | 49 | N/A |
| 9/30/2020 | 370 | 16 | 10 | 52 | N/A |
| 6/30/2020 | 389 | 17 | 11 | 53 | N/A |
| 3/31/2020 | 387 | 17 | 20 | 54 | N/A |
| 12/31/2019 | 385 | 18 | 2 | 44 | N/A |
| 9/30/2019 | 389 | 19 | 2 | 42 | N/A |
| 6/30/2019 | 380 | 18 | -18 | 22 | N/A |
| 3/31/2019 | 380 | 20 | -20 | 33 | N/A |
| 12/31/2018 | 383 | 23 | -5 | 35 | N/A |
| 9/30/2018 | 380 | 22 | 12 | 24 | N/A |
| 6/30/2018 | 398 | 32 | -1 | 31 | N/A |
| 3/31/2018 | 364 | 21 | N/A | 23 | N/A |
| 12/31/2017 | 361 | 20 | N/A | 31 | N/A |
| 9/30/2017 | 356 | 22 | N/A | 31 | N/A |
| 12/31/2016 | 333 | 15 | N/A | 33 | N/A |
| 9/30/2016 | 331 | 12 | N/A | 39 | N/A |
| 12/31/2015 | 329 | 15 | N/A | 30 | N/A |
| 12/31/2014 | 298 | 14 | N/A | 18 | N/A |
| 12/31/2013 | 302 | 17 | N/A | 16 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ACT's forecast earnings growth (9.6% per year) is above the savings rate (0.8%).
Bénéfices vs marché: ACT's earnings (9.6% per year) are forecast to grow slower than the German market (20% per year).
Croissance élevée des bénéfices: ACT's earnings are forecast to grow, but not significantly.
Chiffre d'affaires vs marché: ACT's revenue (5% per year) is forecast to grow slower than the German market (5.3% per year).
Croissance élevée des revenus: ACT's revenue (5% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: ACT's Return on Equity is forecast to be high in 3 years time (23.5%)